 |
26 Diseases |  |
0 Trials |
|
0 Trials |  |
73 News |  |
- AMT-116 ADC / Multitude Therap
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4707;
P1
Dose escalation is ongoing. Clinical trial information: NCT05725291.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2909;
P3
trial, SKB264 was compared with physician's choice of chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in pts with locally recurrent or metastatic TNBC who had received two or more prior therapies including at least one for metastatic setting... Sacituzumab tirumotecan monotherapy demonstrated statistically significant and clinically meaningful PFS and OS benefit over chemotherapy, with a manageable safety profile in pts with heavily pretreated advanced TNBC and limited treatment options.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), tagitanlimab (HBM9167) / Harbour BioMed
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. (Arie Crown Theater) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1381;
P2, P3
A Phase 3 study of SKB264 Q2W plus pembrolizumab vs pembrolizumab in 1L metastatic NSCLC with PD-L1 TPS ? 50% (NCT06170788) is ongoing.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study (Hall GH - Ground Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_8743;
50% (NCT06170788) is ongoing. Abstract is embargoed at this time.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study (Section 48) - Mar 5, 2024 - Abstract #AACR2024AACR_7881;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- Camtobell (belotecan) / Equisnzaroo, Herceptin (trastuzumab) / Roche
Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker (Section 2) - Mar 5, 2024 - Abstract #AACR2024AACR_5554;
This strategy could potentially lead to the development of novel and effective ADC technologies for patients diagnosed with HER2-positive cancers. Moreover, our proposed ADC linker technology can be implemented in additional medical conditions such as other malignancies as well as autoimmune diseases that overexpress targets, other than HER2.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study () - Jan 22, 2024 - Abstract #YIR2024YIR_121;
P1/2, P2,
Higher response rate was seen in mTNBC pts with high TROP2 expression. A Phase 3 study of SKB264 vs.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study (Hemisfair Ballroom 1-2) - Nov 4, 2023 - Abstract #SABCS2023SABCS_347;
P1/2, P2,
Higher response rate was seen in mTNBC pts with high TROP2 expression. A Phase 3 study of SKB264 vs.
- MK-2870 / Merck (MSD)
SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial (Bilbao Auditorium - NCC) - Jul 27, 2023 - Abstract #ESMO2023ESMO_791;
P1/2
Conclusions SKB264 at 5 mg/kg demonstrates a manageable safety profile and promising antitumor activity in pts with pre-treated HR+/HER2- mBC. Two phase 3 studies are currently planned in HR+/HER2- mBC, one in China for pts after at least one chemo for mBC and a second global for pts previously untreated with chemo for mBC, both comparing SKB264 vs investigator selected chemo.
- Camtobell (belotecan) / Equisnzaroo
Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5591;
A decision tree was designed to compare the quality-adjusted life year (QALY) and cost consisting of RIPAC and palliative chemotherapy regimens, such as pegylated liposomal doxorubicin (PLD), gemcitabine (GEM), and topotecan (TOP). Also, to reflect the clinician
- MK-2870 / Merck (MSD)
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study. (On Demand | Hall A; Poster Bd # 102) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3523;
P1/2
TRAEs were mainly hematologic. Phase 3 studies of SKB264 in pts with advanced NSCLC have been planned.
- | Camtobell (belotecan) / Equisnzaroo
Journal: Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study. (Pubmed Central) - Mar 2, 2023
The mechanism is common to camptothecins SN38 (the active metabolite of irinotecan) and belotecan (BLT)...The main camptothecin structural elements implicated in the ribosomal protein interaction are the lactone moiety, the aromatic system and the 10-hydroxyl group. The study provides guidance to the design of modulators of ribosomal proteins L11 and L15, both considered anticancer targets.
- | MK-2870 / Merck (MSD), Camtobell (belotecan) / Equisnzaroo
Nice summary! MK-2870/SKB-264 payload is not belotecan but a belotecan derivative (named KL610023 or T030)(https://t.co/JoV6eRa2Ko) Also a new TROP2 ADC (FZ-AD004) should enter phase 1 in China soon (https://t.co/VmzDmptZcS) (Twitter) - Jan 20, 2023
- | MK-2870 / Merck (MSD), Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Preclinical, Journal: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. (Pubmed Central) - Jan 10, 2023
At the same dose, SKB264's exposure in tumor tissue was 4.6-fold higher than that of IMMU-132. Compared with IMMU-132, the longer half-life of SKB264 had a stronger targeting effect and better antitumor activity, suggesting the better therapeutic potential of SKB264 for treating TROP2-positive tumors.
- SKB264 / Merck (MSD)
Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1637;
P1/2, P3
SKB264 toxicity was mainly hematologic. A Phase 3 study of SKB264 vs investigator selected chemo alone in pts with locally advanced inoperable or metastatic TNBC was initiated (NCT05347134).
- | Camtobell (belotecan) / Equisnzaroo
Journal: The design and discovery of topoisomerase I inhibitors as anticancer therapies. (Pubmed Central) - Jul 31, 2022
Currently, their limitations are being addressed by different stretegies. Future studies should focus not only on developing other active molecules but also on improving the bioavailability and pharmacokinetics of potent synthetic derivatives.
- | SKB-315 / Sichuan Kelun Pharma, SKB264 / Merck (MSD), Camtobell (belotecan) / Equisnzaroo
$MRK 2nd licensed ADC from Kelun likely Claudin18.2 (SKB315) as well, utilizing same belotecan-derived payload as $MRK previously licensed only now disclosed TROP2 ADC SKB264. (Twitter) - Jul 29, 2022
- || irinotecan / Generic mfg.
Review, Journal: Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise. (Pubmed Central) - Oct 14, 2021
These efforts have led to the discovery of potent, first-in-class chemotherapeutic agents inspired by CPT. In addition, the mechanism of action, SAR studies, and recent advances of novel CPT drug delivery systems and antibody drug conjugates are discussed.
- ||||| Camtobell (belotecan) / Equisnzaroo
Trial completion: COMBAT: Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (clinicaltrials.gov) - Aug 9, 2021
P3, N=147, Completed, Sponsor: Chonnam National University Hospital
In addition, the mechanism of action, SAR studies, and recent advances of novel CPT drug delivery systems and antibody drug conjugates are discussed. Recruiting --> Completed
- Camtobell (belotecan) / Equisnzaroo
[VIRTUAL] An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors (Channel 7) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1014;
P1/2
SKB264 has demonstrated encouraging safety and antitumor activity. Study continues to identify dose(s) of SKB264.
- || Camtobell (belotecan) / Equisnzaroo
Clinical, P2b data, Journal, Monotherapy: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer. (Pubmed Central) - Jul 16, 2021
The efficacy/safety of belotecan warrants further evaluation in Phase 3 trials. Belotecan potentially offers an alternative to topotecan for sensitive-relapsed SCLC, particularly in patients aged <65 years, with more advanced disease, or poor performance.
- || Camtobell (belotecan) / OnKor
Clinical, P2b data, Journal: A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. (Pubmed Central) - Apr 16, 2021
P2b
Belotecan potentially offers an alternative to topotecan for sensitive-relapsed SCLC, particularly in patients aged <65 years, with more advanced disease, or poor performance. Belotecan was not inferior to topotecan in terms of overall response for recurrent ovarian cancer.
- | Camtobell (belotecan) / OnKor, ceralasertib (AZD6738) / AstraZeneca
Journal, Combination therapy: Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. (Pubmed Central) - Apr 14, 2021
The combined administration of ATR inhibitor and belotecan proved to be synergistic in our preclinical model. This combination warrants further investigation in a clinical trial, with a particular aim of overcoming chemotherapy resistance in ovarian cancer.
- Herceptin (trastuzumab) / Roche
[VIRTUAL] GlycoConnect™ ADCs based on topoisomerase 1 inhibitor exatecan (SYNtecan E™) show excellent in vivo efficacy and tolerability () - Mar 11, 2021 - Abstract #AACR2021AACR_3321;
Camptothecins form a powerful class of chemotherapy drugs (e.g. irinotecan, topotecan, belotecan), based on their ability to inhibit topoisomerase I. Some camptothecins, such as DXd and SN-38, have also proven powerful payloads for antibody-drug conjugates (ADCs), as exemplified by the recent market approval of Enhertu® and Trodelvy®, respectively...Homogeneous and stable GlycoConnect™ADCs were generated from trastuzumab and SYNtecan E™ and compared head-to-head with DXd or SN-38payload, as well as deruxtecan, the linker-payload applied in Enhertu®...Taken together, these studies demonstrate the potential of SYNtecan E™ for application in stable and site-specific ADCs with excellent therapeutic index.1 van Geel et al. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of NativemAbs Provides Homogeneous and Highly Efficacious Antibody−Drug Conjugates.
- | irinotecan / Generic mfg.
Preclinical, Journal: The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. (Pubmed Central) - Dec 16, 2020
This is the first study to demonstrate usefulness of the HDRA for pancreatic cancer. Using this technique, we could identify novel candidate combination drug regimens that should be effective in treating pancreatic cancer.
- || tamoxifen / Generic mfg., paclitaxel / Generic mfg., irinotecan / Generic mfg.
Review, Journal: Systemic therapy for limited stage small cell lung carcinoma. (Pubmed Central) - Nov 21, 2020
Maintenance therapy following induction with chemotherapy, vandetanib and interferon-alpha have also been attempted...In this review, we discuss the various systemic therapy options in limited stage small cell lung carcinoma, from the historical regimens to the modern-day therapy and promising areas of research. We also discuss the role of growth factors, the optimal number of chemotherapy cycles, the use of prognostic and predictive factors, the optimal timing of chemotherapy and the treatment of special populations of patients including older patients, and patients with comorbidities.
- | irinotecan / Generic mfg.
Biomarker, Review, Journal: Irinotecan: 25 years of cancer treatment. (Pubmed Central) - Jul 2, 2020
This review highlights recent discoveries in the field of IRT and its derivatives, including analogues of the active metabolite SN38 (such as FL118), the recently approved liposomal form Nal-IRI and SN38-based immuno-conjugates currently in development (such as sacituzumab govitecan)...It offers a large range of drug combinations with cytotoxic agents, targeted products and immuno-active biotherapeutics, to treat a variety of advanced solid carcinoma, sarcoma and cancers with progressive central nervous system diseases. A quarter of century after its first launch, IRT remains an essential anticancer drug, largely prescribed, useful to many patients and scientifically inspiring.
- | Camtobell (belotecan) / OnKor
Journal, PARP Biomarker: CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer. (Pubmed Central) - Jun 26, 2020
This is the first report of CKD-602 having an antitumor effect in cervical cancer in both an in vitro and in vivo models. The results of this study indicate that CKD-602 may be a novel potential drug, targeting cervical cancer, providing new opportunities in the development of new therapeutic strategies.
- Camtobell (belotecan) / OnKor
[VIRTUAL] SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies. (Poster Board 389) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1606;
P1/2
The enrollment will began in Mar 2020 in USA sites. Research Funding: KLUS Pharm Inc.
- | irinotecan / Generic mfg.
Preclinical, Journal: Development of an enzyme‑linked immunosorbent assay for camptothecin. (Pubmed Central) - Dec 20, 2019
The cross‑reactivity results suggested that the assay developed in the present study possessed a high sensitivity to camptothecin. Therefore, this immunoassay technique may be suitable for monitoring the levels of camptothecin in compound analysis, clinical applications, and analyses of food and environmental samples.
- Camtobell (belotecan) / OnKor
CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in murine cervical cancer () - Oct 16, 2019 - Abstract #ESGO2019ESGO_1704;
Conclusion This is the first report of CKD-602 having an antitumor effect in cervical cancer in both an in vitro and in vivo models. The results of this study indicate that CKD-602 may be a novel potential drug, targeting cervical cancer, providing new opportunities in the development of new therapeutic strategies.
- | Camtobell (belotecan) / OnKor
Preclinical, Journal: The role of p53 status on the synergistic effect of CKD-602 and cisplatin on oral squamous cell carcinoma cell lines. (Pubmed Central) - Jul 4, 2019
From these results, it was suggested that the combination of CKD-602 with cisplatin might be a potential therapeutic strategy for OSCC. In particular, cell line-specific therapy is necessary because of the differences in treatment response based on p53 status.
- ||| Camtobell (belotecan) / Equisnzaroo
Trial completion, Trial completion date, Monotherapy: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Dec 27, 2018
P2b, N=164, Completed, Sponsor: Chong Kun Dang Pharmaceutical
In particular, cell line-specific therapy is necessary because of the differences in treatment response based on p53 status. Recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018
- |||| Camtobell (belotecan) / Equisnzaroo
Trial completion, Phase classification: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial (clinicaltrials.gov) - Sep 22, 2016
P2b, N=141, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 Recruiting --> Completed | Phase classification: P2 --> P2b
- Camtobell (belotecan) / Equisnzaroo
Trial primary completion date: A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer (clinicaltrials.gov) - Feb 10, 2016
P1/2, N=45, Recruiting, Sponsor: Gachon University Gil Medical Center
Recruiting --> Completed | Phase classification: P2 --> P2b Trial primary completion date: Jul 2014 --> Jul 2018
- || Camtobell (belotecan) / Equisnzaroo
Trial primary completion date, Monotherapy: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Sep 24, 2015
P2b, N=176, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: Jul 2014 --> Jul 2018 Trial primary completion date: Feb 2015 --> Dec 2017
- | Camtobell (belotecan) / Equisnzaroo
Trial completion, Combination therapy: Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=42, Completed, Sponsor: Yonsei University
Trial primary completion date: Feb 2015 --> Dec 2017 Recruiting --> Completed
- || Camtobell (belotecan) / Equisnzaroo
Trial primary completion date, Monotherapy: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Oct 10, 2014
P2b, N=176, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Feb 2015
- || Camtobell (belotecan) / Equisnzaroo
Trial primary completion date, Monotherapy: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Oct 4, 2014
P2b, N=176, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: Sep 2015 --> Feb 2015 Trial primary completion date: Feb 2015 --> Sep 2015
- || Camtobell (belotecan) / Equisnzaroo
Trial primary completion date, Monotherapy: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Sep 29, 2014
P2b, N=176, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Feb 2014 --> Feb 2015
- Camtobell (belotecan) / Equisnzaroo
Enrollment change, Metastases: Safety Study of S-CKD602 in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 17, 2013
P1, N=45, Completed, Sponsor: University of Pittsburgh
Trial primary completion date: Feb 2014 --> Feb 2015 N=70 --> 45
- Camtobell (belotecan) / Equisnzaroo
New P1/2 trial: A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer (clinicaltrials.gov) - Feb 3, 2013
P1/2, N=45, Recruiting, Sponsor: Gachon University Gil Medical Center
- ||||| Camtobell (belotecan) / Equisnzaroo
New P2 trial: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial (clinicaltrials.gov) - Jun 26, 2012
P2, N=140, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- Camtobell (belotecan) / Equisnzaroo
Enrollment change: Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix (clinicaltrials.gov) - Apr 24, 2012
P2, N=16, Completed, Sponsor: Sokbom Kang
N=70 --> 45 N=53 --> 16
- Camtobell (belotecan) / Equisnzaroo
Trial completion: Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix (clinicaltrials.gov) - Apr 24, 2012
P2, N=16, Completed, Sponsor: Sokbom Kang
N=53 --> 16 Recruiting --> Completed
- |||||| Camtobell (belotecan) / Equisnzaroo
New P2b trial, Monotherapy: A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Dec 21, 2011
P2b, N=176, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- |||| Camtobell (belotecan) / Equisnzaroo
Trial completion, Metastases: Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy (clinicaltrials.gov) - Dec 20, 2011
P2, N=52, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed Enrolling by invitation --> Completed